Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pfizer : CytoReason teams with Pfizer on drug discovery

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/12/2019 | 04:44am EDT

The Israeli company will earn over $10 million for its machine learning cell-centered models of the immune system.

Israeli machine learning company CytoReason, which has developed cell-centered models of the immune system for drug discovery has entered into a collaboration agreement with Pfizer Inc. (NYSE:PFE). Pfizer will pay CytoReason amounts, "equaling up to low double digit millions of US$ for technology access fees, research support and certain success-based payments."

The Tel Aviv-based company`s proprietary platform helps rebuild lost cellular information from gene expression data and associates genes to specific cells. This information is then integrated with additional omics and literature data to create a cell-based model of the trial-specific immune response. Integration with the CytoReason disease model empowers the study analytics and allows the model to learn and improve, leading to robust target discovery, drug response biomarkers and indication selection.

CytoReason CEO David Harel said, The collaboration with Pfizer will further strengthen our models in our core therapeutic areas. This will be our fifth major partnership, which we believe will help make our model unparalleled in its accuracy for assets across the pipeline. CytoReasons model brings together thousands of samples on a cell-protein-gene level, allowing for fast and accurate insights.

We believe that CytoReasons platform has the potential to offer valuable insights that may be applied to our research into the human immune system, said Michael Vincent, CSO, Inflammation & Immunology, Pfizer. Leveraging technologies such as this can help us understand disease and prioritize targets, and support our mission of bringing innovative new therapies to patients who need them.

CytoReason was represented by Adv Yael Baratz from Pearl Cohen Zedek Latzer Baratz law firm.

(c) 2019 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
04:52aPFIZER : Regulator OKs immunotherapies developed by multinational pharma compani..
AQ
03/25China will open further to foreign investment - premier assures global execut..
RE
03/23PFIZER : buys stake in French gene therapy company Vivet
AQ
03/21PFIZER : Description Notice of exempt solicitation. Definitive material.
PU
03/21ERNESTO BERTARELLI : French healthcare group Stallergenes to be bought out by Be..
RE
03/21PFIZER : Adds to Streak of Deals in Gene Therapies
DJ
03/20Merck KGaA, Pfizer End Phase III Trial in Previously Untreated Advanced Ovari..
DJ
03/20PFIZER : Adds to Big Pharma's Gene-Therapy Deal Streak
DJ
03/20PFIZER : Takes 15% Stake in Gene-Therapy Biotech Vivet Therapeutics
DJ
03/20PFIZER : Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeu..
BU
More news
Financials ($)
Sales 2019 53 331 M
EBIT 2019 19 994 M
Net income 2019 12 143 M
Debt 2019 32 038 M
Yield 2019 3,42%
P/E ratio 2019 19,29
P/E ratio 2020 16,76
EV / Sales 2019 4,96x
EV / Sales 2020 4,85x
Capitalization 233 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 44,1 $
Spread / Average Target 5,4%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-4.03%232 565
JOHNSON & JOHNSON5.86%363 761
NOVARTIS10.09%237 528
ROCHE HOLDING LTD.10.42%232 888
MERCK AND COMPANY7.77%212 563
ELI LILLY AND COMPANY12.23%134 522